• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Herz >Renal denervation for mild-moderate treatment-resistant hypertension A timely intervention?
【24h】

Renal denervation for mild-moderate treatment-resistant hypertension A timely intervention?

机译：适用于温和 - 中等治疗耐药高血压的肾去干预及时干预？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Renal denervation (RDN) has been proposed as a novel antihypertensive intervention for treating resistant hypertension. It remains to be investigated which patient groups can potentially benefit from RDN. The present study aimed to evaluate the efficacy and safety of RDN in patients with mild-moderate resistant hypertension, i. e., systolic office blood pressure (BP) of 140-160 mm Hg despite treatment with three antihypertensive drugs including one diuretic, or mean systolic BP by ambulatory BP monitoring (ABPM) of 135-150 mm Hg. Methods We evaluated data from four relevant clinical studies, all conducted in Europe, comprising 185 eligible patients. The patients' age was 62.1 +/- 10.3 years and 73% were male (RDN group n = 149, control group n = 36). Results A self-control comparison showed that RDN led to significantly reduced ABPM at the 6-month follow-up (systolic ABPM: 147.3 +/- 13.4 mm Hg vs. 136.9 +/- 15.5 mm Hg; diastolic ABPM: 81.1 +/- 9.6 mm Hg vs. 76.2 +/- 9.7 mm Hg; p < 0.001). RDN was associated with a greater improvement in ABPM as compared with that in the control group ( increment systolic-ABPM: -10.4 +/- 9.4 vs. -3.5 +/- 9.6 mm Hg, p < 0.001; increment diastolic-ABPM: -5 +/- 5.8 vs. -2.1 +/- 5.5 mm Hg; p = 0.005, respectively). The decrease of office BP in the RDN group was also statistically significant. RDN led to a reduced number of antihypertensive medications. No severe adverse events were found during follow-up. Regression analysis showed that the available baseline characteristics did not correlate with the ABPM improvement after RDN. Conclusion RDN appears to be a safe and effective intervention for patients with mild-moderate resistant hypertension; however, randomized studies are warranted.
机译：背景技术已经提出了肾脏消除物（RDN）作为治疗抗性高血压的新型抗高血压干预。它仍有待研究哪些患者群体可能会受益于RDN。本研究旨在评估RDN在患有轻度 - 中度抗性高血压患者中的疗效和安全性，i。即，尽管用三种抗高血压药物治疗，但在包括一种利尿剂，或者通过动态BP监测（ABPM）为135-150 mm Hg，均为340-160 mm Hg的收缩压办公室血压（BP）。方法我们评估了来自四项相关临床研究的数据，所有在欧洲进行，包括185名符合条件的患者。患者的年龄为62.1 +/- 10.3岁，73％是男性（RDN组n = 149，对照组n = 36）。结果自我控制比较表明，RDN在6个月的随访中导致ABPM显着减少（收缩期：147.3 +/- 13.4 mm Hg与136.9 +/- 15.5 mm Hg;舒张压缩动ABPM：81.1 +/- 9.6 mm Hg vs. 76.2 +/- 9.7 mm hg; p <0.001）。与对照组相比，RDN与ABPM的更大改善有关（增量收缩压 - ABPM：-10.4 +/- 9.4与-3.5 +/- 9.6 mm Hg，P <0.001;增量舒张 - ABPM： - 5 +/- 5.8与-2.1 +/- 5.5 mm hg; p = 0.005分别）。 RDN组中的办公BP减少也存在统计学意义。 RDN导致减少抗高血压药物数量。随访期间没有发现严重的不良事件。回归分析表明，可用的基线特性与RDN后的ABPM改进无关。结论RDN似乎是一种安全有效的抗性高血压患者的干预;但是，有必要进行随机研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号